Anastrozole
Product Images NDC 76519-1224

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 76519-1224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by H.j. Harkins Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (76519 1224 Ppac Label)

ANASTROZOLE 1 mg tablet label by H.J. Harkins Company, Inc., with product NDC 76519-1224-XX. The label includes dosage strength, multiple barcodes, lot number AB00CD, and manufacturing information listing ACCORD and an NDC code 16729-0035-10. The label also shows cautionary text about federal law and safe storage instructions, along with multiple small repeat labels for pharmacy use.*

FDA Label Image

Disimage (Disimage)

Chemical structure of anastrozole showing a benzene ring with attached nitrile and methyl groups, and a triazole ring connected by an ethyl linker.*

FDA Label Image

Figure1 (Figure1)

A survival curve chart comparing disease-free survival over months between anastrozole and tamoxifen treatments. The x-axis represents disease-free survival in months from 0 to 90, and the y-axis shows the proportion alive and disease-free from 0.0 to 1.0. Two lines depict treatment groups, with anastrozole as a solid line and tamoxifen as a dashed line. The number of patients at risk for each treatment group is listed below the x-axis at various time points.*

FDA Label Image

Figure2 (Figure2)

A Kaplan-Meier survival curve comparing disease-free survival in months between two randomized treatments: anastrozole and tamoxifen. The y-axis shows the proportion of patients alive and disease-free, while the x-axis indicates time in months, spanning up to 96 months. The graph includes a legend distinguishing the two treatment groups and a table below listing the number of patients at risk at various time points for each treatment.*

FDA Label Image

Figure3 (Figure3)

A Kaplan-Meier survival curve chart comparing the proportion of patients event-free over time (up to 120 months) for two treatments: Anastrozole and Tamoxifen. The solid line represents Anastrozole, and the dashed line represents Tamoxifen. Below the graph, the number of patients at risk is shown at several time points for both treatments.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier survival curve comparing the proportion of patients remaining event-free over time (in months) between two randomized treatments: Anastrozole and Tamoxifen. The horizontal axis shows time to event up to 120 months, and the vertical axis shows the proportion event free ranging from 0.50 to 1.00. The number of patients at risk is listed below the time points for each treatment group.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier survival curve comparing the proportion of patients not progressing over time in months between two randomized treatments: Anastrozole and Tamoxifen. The graph shows the progression-free proportion on the y-axis and time to progression in months on the x-axis, with step lines representing each treatment group's progression status over the study period.*

FDA Label Image

Figure6 (Figure6)

A Kaplan-Meier survival curve chart showing the proportion of patients not progressing over time in months. The chart compares two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, while the y-axis indicates the proportion not progressed, ranging from 0 to 1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.